Data Publications & Literature

Highlights

ASCO 2024, Ivonescimab combined with chemo…

ASCO 2024, The Safety and Efficacy of Ivonescimab…

JAMA 2024, Ivonescimab + Chemo in NSCLC…

Current Publications

Title
Author
Congresses / Journals
Type
Category
Title
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR-TKIs treatment: a randomized, double-blind, multi-center, phase 3 trial (HARMONi-A study)
Author
Zhang L, et al.
Congresses / Journals
ASCO 2024
Type
Oral Presentation
Category
Non-Small Cell Lung Cancer
Title
The Safety and Efficacy of Ivonescimab in Combination With Chemotherapy as First-Line Treatment for Advanced Biliary Tract Cancer
Author
Ying J, et al.
Congresses / Journals
ASCO 2024
Type
Poster
Category
Biliary Tract Cancer
Title
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant - A Randomized Clinical Trial
Author
Fang W, et al.
Congresses / Journals
JAMA Network
Type
Abstract
Article
Category
Non-Small Cell Lung Cancer
Title
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-­1/VEGF-­A bispecific antibody, in patients with advanced solid tumors
Author
Frentzas S, et al.
Congresses / Journals
Journal for Immunotherapy of Cancer (JITC)
Type
Abstract
Article
Category
Advanced Solid Tumors
Title
Intracranial Activity of Ivonescimab Alone or In Combination with Platinum Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer and Brain Metastases
Author
Zhang L, et al.
Congresses / Journals
ELCC 2024
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
Phase 2 Results of Ivonescimab, a Novel PD-1/VEGF Bispecific in Combination with Chemotherapy for First Line treatment of Patients with Advanced/Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Author
Zhang L, et al.
Congresses / Journals
ELCC 2024
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naïve NSCLC
Author
Wang L, et al.
Congresses / Journals
Journal of Thoracic Oncology, Vol 19.
Type
Article
Peer Reviewed
Category
Non-Small Cell Lung Cancer
Title
Mechanism of Action of Ivonescimab (AK112/SMT112): A First-in-Class Tetravalent Fc-silent Bispecific Antibody with Dual Blockade of PD-1 and VEGF that Promotes Cooperative Biological Effects
Author
Zhong T, et al.
Congresses / Journals
SITC 2023
Type
Poster
Category
Mechanism of Action
Title
HARMONi: A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-Squamous NSCLC Who Have Failed to EGFR-TKI Treatment
Author
Fang W, et al.
Congresses / Journals
ESMO 2023
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
HARMONi-3: A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
Author
Riess J, et al.
Congresses / Journals
AACR-NCI-EORTC 2023
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
Mechanism of Action of Ivonescimab (AK112/SMT112): A First-in-Class Tetravalent Bispecific Antibody with Dual Blockade of PD-1 and VEGF that Promotes Cooperative Biological Effects
Author
Zhong T, et al.
Congresses / Journals
AACR-NCI-EORTC 2023
Type
Poster
Category
Mechanism of Action
Title
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
Author
Zhao Y, et al.
Congresses / Journals
eClinicalMedicine (Part of The Lancet Discovery Science), Vol 62. 2023
Type
Article
Peer Reviewed
Category
Non-Small Cell Lung Cancer
Title
Phase II results of Ivonescimab (AK112/SMT112) a novel PD-1/VEGF bispecific in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK
Author
Zhang L, et al.
Congresses / Journals
ASCO 2023
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies
Author
Zhong T, et al.
Congresses / Journals
SITC 2022
Type
Poster
Category
Mechanism of Action
Title
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first or second-line therapy for advanced non-small cell lung cancer (NSCLC)
Author
Zhou C, et al.
Congresses / Journals
ASCO 2022
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
A phase II study of AK112 (PD-1/VEGF Bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)
Author
Zhao Y, et al.
Congresses / Journals
ASCO 2022
Type
Poster
Category
Non-Small Cell Lung Cancer
Title
Safety and Efficacy of AK112 an Anti-PD-1VEGF-A Bispecific Antibody In Patients With Advanced Solid Tumors In A Phase I Dose Escalation Study
Author
Coward J, et al.
Congresses / Journals
ASCO 2021
Type
Abstract
Poster
Category
Advanced Solid Tumors
Title
A Phase I Study of AK112, a Bispecific Antibody that Targets PD-1 and VEGF Co-expressing T cells, in Patients with Advanced Solid Tumors
Author
Coward J, et al.
Congresses / Journals
ASCO 2020
Type
Poster
Category
Advanced Solid Tumors

Ivonescimab is an investigational therapy that is not approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).